Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice

NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-01, Vol.13, p.833705-833705
Main Authors: Wang, Si-Wei, Lan, Tian, Chen, Hang-Fei, Sheng, Hao, Xu, Chun-Yi, Xu, Li-Feng, Zheng, Fang, Zhang, Feng
Format: Article
Language:English
Subjects:
AMPK
limonin
lipid accumulation
NAFLD
Pharmacology
SREBP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3
cites cdi_FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3
container_end_page 833705
container_issue
container_start_page 833705
container_title Frontiers in pharmacology
container_volume 13
creator Wang, Si-Wei
Lan, Tian
Chen, Hang-Fei
Sheng, Hao
Xu, Chun-Yi
Xu, Li-Feng
Zheng, Fang
Zhang, Feng
description NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.
doi_str_mv 10.3389/fphar.2022.833705
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8a95095c2b4547f1a667af4bae1b0481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_8a95095c2b4547f1a667af4bae1b0481</doaj_id><sourcerecordid>2627479985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3</originalsourceid><addsrcrecordid>eNpVkUFv1DAQhSMEolXpD-CCfOTQ3XpiO7YvSKuWZVdsBQc4cLImjr3rKomDk1Ti3-N226r1xdbze9-M9IriI9AlY0pf-uGAaVnSslwqxiQVb4pTqCq20ArKty_eJ8X5ON7SfJjWrOLvixMmgNOqhNPizy50sQ_9BcGerG5-ficrO4U7nGK6INv-EOowjWTjBpyCJbswhCY77NzNbVZiT0JPNmF_IGucyHVwE1m7htwE6z4U7zy2ozt_vM-K3-uvv642i92Pb9ur1W5heSWmhVMeZCOsrKlQlCFIi-CV975BzBr34K1wFYOqYQCSalHaGhvqGgArkZ0V2yO3iXhrhhQ6TP9MxGAehJj2BlNevnVGoRY5b8uaCy49YFVJ9LxGBzXlCjLry5E1zHXnGuv6KWH7Cvr6pw8Hs493RinQQvMM-PwISPHv7MbJdGG0rm2xd3EeTVmVkkutlchWOFptiuOYnH8eA9TcN2weGjb3DZtjwznz6eV-z4mnPtl_SgeiAw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627479985</pqid></control><display><type>article</type><title>Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice</title><source>PubMed Central Free</source><creator>Wang, Si-Wei ; Lan, Tian ; Chen, Hang-Fei ; Sheng, Hao ; Xu, Chun-Yi ; Xu, Li-Feng ; Zheng, Fang ; Zhang, Feng</creator><creatorcontrib>Wang, Si-Wei ; Lan, Tian ; Chen, Hang-Fei ; Sheng, Hao ; Xu, Chun-Yi ; Xu, Li-Feng ; Zheng, Fang ; Zhang, Feng</creatorcontrib><description>NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2022.833705</identifier><identifier>PMID: 35140621</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>AMPK ; limonin ; lipid accumulation ; NAFLD ; Pharmacology ; SREBP</subject><ispartof>Frontiers in pharmacology, 2022-01, Vol.13, p.833705-833705</ispartof><rights>Copyright © 2022 Wang, Lan, Chen, Sheng, Xu, Xu, Zheng and Zhang.</rights><rights>Copyright © 2022 Wang, Lan, Chen, Sheng, Xu, Xu, Zheng and Zhang. 2022 Wang, Lan, Chen, Sheng, Xu, Xu, Zheng and Zhang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3</citedby><cites>FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819594/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819594/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35140621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Si-Wei</creatorcontrib><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Chen, Hang-Fei</creatorcontrib><creatorcontrib>Sheng, Hao</creatorcontrib><creatorcontrib>Xu, Chun-Yi</creatorcontrib><creatorcontrib>Xu, Li-Feng</creatorcontrib><creatorcontrib>Zheng, Fang</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><title>Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.</description><subject>AMPK</subject><subject>limonin</subject><subject>lipid accumulation</subject><subject>NAFLD</subject><subject>Pharmacology</subject><subject>SREBP</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUFv1DAQhSMEolXpD-CCfOTQ3XpiO7YvSKuWZVdsBQc4cLImjr3rKomDk1Ti3-N226r1xdbze9-M9IriI9AlY0pf-uGAaVnSslwqxiQVb4pTqCq20ArKty_eJ8X5ON7SfJjWrOLvixMmgNOqhNPizy50sQ_9BcGerG5-ficrO4U7nGK6INv-EOowjWTjBpyCJbswhCY77NzNbVZiT0JPNmF_IGucyHVwE1m7htwE6z4U7zy2ozt_vM-K3-uvv642i92Pb9ur1W5heSWmhVMeZCOsrKlQlCFIi-CV975BzBr34K1wFYOqYQCSalHaGhvqGgArkZ0V2yO3iXhrhhQ6TP9MxGAehJj2BlNevnVGoRY5b8uaCy49YFVJ9LxGBzXlCjLry5E1zHXnGuv6KWH7Cvr6pw8Hs493RinQQvMM-PwISPHv7MbJdGG0rm2xd3EeTVmVkkutlchWOFptiuOYnH8eA9TcN2weGjb3DZtjwznz6eV-z4mnPtl_SgeiAw</recordid><startdate>20220124</startdate><enddate>20220124</enddate><creator>Wang, Si-Wei</creator><creator>Lan, Tian</creator><creator>Chen, Hang-Fei</creator><creator>Sheng, Hao</creator><creator>Xu, Chun-Yi</creator><creator>Xu, Li-Feng</creator><creator>Zheng, Fang</creator><creator>Zhang, Feng</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220124</creationdate><title>Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice</title><author>Wang, Si-Wei ; Lan, Tian ; Chen, Hang-Fei ; Sheng, Hao ; Xu, Chun-Yi ; Xu, Li-Feng ; Zheng, Fang ; Zhang, Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>AMPK</topic><topic>limonin</topic><topic>lipid accumulation</topic><topic>NAFLD</topic><topic>Pharmacology</topic><topic>SREBP</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Si-Wei</creatorcontrib><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Chen, Hang-Fei</creatorcontrib><creatorcontrib>Sheng, Hao</creatorcontrib><creatorcontrib>Xu, Chun-Yi</creatorcontrib><creatorcontrib>Xu, Li-Feng</creatorcontrib><creatorcontrib>Zheng, Fang</creatorcontrib><creatorcontrib>Zhang, Feng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Si-Wei</au><au>Lan, Tian</au><au>Chen, Hang-Fei</au><au>Sheng, Hao</au><au>Xu, Chun-Yi</au><au>Xu, Li-Feng</au><au>Zheng, Fang</au><au>Zhang, Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2022-01-24</date><risdate>2022</risdate><volume>13</volume><spage>833705</spage><epage>833705</epage><pages>833705-833705</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>35140621</pmid><doi>10.3389/fphar.2022.833705</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2022-01, Vol.13, p.833705-833705
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8a95095c2b4547f1a667af4bae1b0481
source PubMed Central Free
subjects AMPK
limonin
lipid accumulation
NAFLD
Pharmacology
SREBP
title Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A53%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limonin,%20an%20AMPK%20Activator,%20Inhibits%20Hepatic%20Lipid%20Accumulation%20in%20High%20Fat%20Diet%20Fed%20Mice&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Wang,%20Si-Wei&rft.date=2022-01-24&rft.volume=13&rft.spage=833705&rft.epage=833705&rft.pages=833705-833705&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2022.833705&rft_dat=%3Cproquest_doaj_%3E2627479985%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-e8f17d5c7b05803a17ca1f8fffdaab054f1fc5e6316d31170952cbad0ed11c7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2627479985&rft_id=info:pmid/35140621&rfr_iscdi=true